Compare RWT & SCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RWT | SCTX |
|---|---|---|
| Founded | 1994 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 597.9M | 536.5M |
| IPO Year | 1996 | 2026 |
| Metric | RWT | SCTX |
|---|---|---|
| Price | $4.43 | $30.20 |
| Analyst Decision | Buy | |
| Analyst Count | 7 | 0 |
| Target Price | ★ $6.82 | N/A |
| AVG Volume (30 Days) | ★ 1.4M | 209.7K |
| Earning Date | 04-29-2026 | N/A |
| Dividend Yield | ★ 12.83% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $26.59 | N/A |
| Revenue Next Year | $22.21 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.19 | $17.31 |
| 52 Week High | $6.97 | $39.60 |
| Indicator | RWT | SCTX |
|---|---|---|
| Relative Strength Index (RSI) | 33.18 | 56.22 |
| Support Level | $4.19 | $19.09 |
| Resistance Level | $4.93 | $34.64 |
| Average True Range (ATR) | 0.10 | 4.80 |
| MACD | -0.02 | 0.00 |
| Stochastic Oscillator | 0.00 | 52.19 |
Redwood Trust Inc is a specialty finance company focused on several distinct areas of housing credit. The company delivers customized housing credit investments to a diverse mix of investors through securitization platforms, whole-loan distribution activities, and its publicly traded securities. The company has four reportable segments: Sequoia Mortgage Banking, CoreVest Mortgage Banking, Redwood Investments, and Legacy Investments. Maximum revenue is generated from the Sequoia Mortgage Banking segment, comprising a mortgage loan conduit that acquires residential consumer loans from third-party originators for subsequent sale to whole loan buyers, securitization through its SEMT private-label securitization program, or transfer into its Redwood Investments portfolio.
Scribe Therapeutics Inc is a clinical-stage biotechnology company engaged in the development of in vivo CRISPR-based genetic medicines. Its research and development activities focus on cardiovascular and metabolic diseases, including atherosclerotic cardiovascular disease (ASCVD). The company's product pipeline includes STX-1150, a CRISPR-based product candidate that utilizes its ELXR epigenetic silencing technology.